Skyscraper-08 yields a positive result that – with caveats – looks decent on a cross-trial basis too.

Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.

Three years after licensing in the IAP inhibitor xevinapant Merck KGaA will find out if the deal was worth it.

Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.